To recover your password please fill in your email address
Please fill in below form to create an account with us
A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours (ANZUP1302).
See ANZCTR for full trial details >
|
Trial Summary: |
To determine if accelerated BEP (Bleomycin, Etoposide and Cisplatin) is superior to standard BEP as first-line chemotherapy for intermediate and poor-risk metastatic germ cell tumours. |
|
Supported By: |
Cancer Australia |
|
Eligibility: |
Men ≤ 16 years but 45 years ≥ with metastatic germ cell tumours (non-seminoma and seminoma) or intermediate or poor prognostic category with adequate bone marrow, hepatic and renal function. |
|
Registration ID: |
ANZCTR12613000496718 |
|
Participation: |
International |
|
Australian Lead Group: |
ANZUP |
|
Status: |
Recruiting |
|
Activation Date: |
19/02/2014 |
|
Chairs: |
A/Prof Peter Grimison |
|
Contact: |